Skip to main content
Digital Seminar

Evidence-Based Therapy Practices in Psilocybin-Assisted Interventions


Faculty:
Matthew W. Johnson, PhD
Duration:
1 Hour 04 Minutes
Copyright:
Jul 28, 2022
Product Code:
NOS096251
Media Type:
Digital Seminar
Access:
Never expires.


Description

This recording will explore modern approaches to psychotherapy using the classic psychedelic compound psilocybin. This includes a variety of disorders including substance use disorders, affective, and anxiety disorders. Methods for assuring safety as well as maximizing efficacy will be reviewed.

CPD

Planning Committee Disclosure - No relevant relationships All members of the PESI, Inc. planning committee have provided disclosures of financial relationships with ineligible organizations and any relevant non-financial relationships prior to planning content for this activity. None of the committee members had relevant financial relationships with ineligible companies or other potentially biasing relationships to disclose to learners. For speaker disclosures, please see the faculty biography.


CPD

PESI Australia, in collaboration with PESI in the USA, offers quality online continuing professional development events from the leaders in the field at a standard recognized by professional associations including psychology, social work, occupational therapy, alcohol and drug professionals, counselling and psychotherapy. On completion of the training, a Professional Development Certificate is issued after the individual has answered and submitted a quiz and course evaluation. This program is worth 1.25 hours CPD for points calculation by your association.



Handouts

Faculty

Matthew W. Johnson, PhD's Profile

Matthew W. Johnson, PhD Related seminars and products


Matthew W. Johnson, PhD, is The Susan Hill Ward Endowed Professor of Psychedelics and Consciousness Research at Johns Hopkins. Working with psychedelics since 2004, he is one of the world’s most widely published experts on psychedelics. He has published research on psychedelics and mystical experience, personality change, tobacco smoking cessation, cancer distress treatment, and depression treatment. In 2021 he received, as principal investigator, the first grant in 50 years from the US government for a treatment study with a classic psychedelic, specifically psilocybin in treatment of tobacco addiction. He is also known for his expertise in behavioral economics, addiction, sexual risk behavior, and research with a wide variety of drug classes. He’s been interviewed by Anderson Cooper on 60 Minutes, the New York Times, the Washington Post, the Wall Street Journal, CNN, NPR, Fox News, Fox Business News, BBC, and was featured in Michael Pollan’s book, How to Change Your Mind.


Speaker Disclosures:
Financial: Dr. Matthew Johnson has an employment relationship with Johns Hopkins University School of Medicine and receives a consulting fee from Field Trip Psychedelics Inc, AJNA Labs LLC, AWAKN Life Sciences Inc, Beckley Psychedelic Ltd, Entheogen Biomedical Corp, and Otsuka Pharmaceutical Development & Commercialization Inc. He receives grants from NIH/NIDA, Mydecine Innovations Group Inc., Heffter Research Institute, Steven and Alexandra Cohen Foundation, Tim Ferriss Collaborative, Usona Institute, Realm of Caring Foundation, and Microdoz Therapy, Inc. Dr. Johnson receives a speaking honorarium from Psychotherapy Networker and PESI, Inc. All relevant financial relationships with ineligible organizations have been mitigated.

Non-financial: Dr. Matthew Johnson is a member of the Society for Quantitative Analysis of Behavior, the American Psychological Association, the Association for Behavior Analysis International, the College on Problems of Drug Dependence, the International Study Group Investigating Drugs as Reinforcers, and the International Society for Research on Psychedelics.


Objectives

  1. Analyze at least 2 disorders that are being studied in regard to psilocybin-assisted psychotherapy. 
  2. Determine at least 2 risks in the administration of psychedelics, specifically psilocybin.
  3. Assess at least 2 ways to maximize the efficacy of psilocybin in psilocybin-assisted psychotherapy.

Outline

  • Safety guidelines for psilocybin 
  • Evidence for efficacy of psilocybin in psychotherapy 
  • Guiding Psilocybin-assisted sessions 

Target Audience

  • Counsellors
  • Marriage & Family Therapists
  • Nurses
  • Nurse Practitioners
  • Physicians
  • Psychologists
  • Social Workers
  • Other Behavioral Health Professionals

Please wait ...

Back to Top